|1st October 2020||Stanley C Erck||2||Open or private sale||$108.57||$217.13|
|30th September 2020||Stanley C Erck||800||Open or private sale||$114.73||$91,784.00|
|30th September 2020||Stanley C Erck||517||Open or private sale||$107.56||$55,608.99|
|30th September 2020||Stanley C Erck||1,676||Open or private sale||$110.54||$185,269.73|
|30th September 2020||Stanley C Erck||5,138||Open or private sale||$108.56||$557,796.69|
|30th September 2020||Stanley C Erck||1,500||Open or private sale||$109.54||$164,304.00|
|30th September 2020||Stanley C Erck||800||Open or private sale||$112.65||$90,118.00|
|30th September 2020||Stanley C Erck||100||Open or private sale||$115.65||$11,565.00|
|30th September 2020||Stanley C Erck||100||Open or private sale||$115.43||$11,543.00|
|30th September 2020||Stanley C Erck||700||Open or private sale||$114.20||$79,940.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Novavax, Inc. is a late-stage biotechnology company. It focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. Its vaccine candidates include ResVax and NanoFlu.